ScreenerHero

ZLNA Zelluna ASA

OSL · NO · Healthcare · Biotechnology · zelluna.com
19.20NOK-1.29%Mkt Cap: 53.59M $P/E: —

Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
INSM
Insmed Incorporated
$22.98BUSD
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap53.59M USD
Enterprise Value44.83M USD
Revenue (TTM)748 USD
Gross Profit748 USD
Net Income (TTM)-13.15M USD
Revenue/Share0.00 NOK
Last Price19.20 NOK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees15
CountryNO
SectorHealthcare
IndustryBiotechnology
ISINNO0013524942
Valuation
P/E (Trailing)—
P/E (Forward)-5.15
PEG—
EV/EBITDA-4.44
EV/Revenue59945.27
P/S71665.23
P/B7.52
EPS (TTM)-4.90
EPS (Forward)-3.73
52W Range
8.20440% of range35.80
52W High35.80 NOK
52W Low8.204 NOK
Profitability
Gross Margin100.00%
Oper. Margin-1383137.50%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-46.84%
ROA-45.67%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.93M USD
CapEx (TTM)33.56K USD
FCF Margin-783173.45%
FCF Yield-10.93%
Net Debt-7.96M USD
Net Debt/EBITDA0.79
Balance Sheet
Debt/Equity0.00
Current Ratio12.13
Quick Ratio11.93
Book Value/Sh2.55 NOK
Cash/Share2.93 NOK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 NOK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateApr 1, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.29.86M
Float11.63M
Insiders40.60%
Institutions15.72%
Technical
SMA 5021.93 (-12.4%)
SMA 20019.58 (-1.9%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)94.77K
Avg Vol (10d)17.64K
Technical Indicators
RSI (14)39.5
MACD-0.7310
MACD Signal-0.6793
MACD Hist.-0.0517
BB Upper21.58 NOK
BB Middle20.27 NOK
BB Lower18.96 NOK
BB Width12.95%
ATR (14)1.366 NOK
Vol Ratio (20d)0.55x